CymaBay Therapeutics Inc (NASDAQ:CBAY)

6.28
Delayed Data
As of Jun 14
 -0.47 / -6.96%
Today’s Change
4.82
Today|||52-Week Range
15.00
-20.20%
Year-to-Date
CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study
Jun 12 / Zacks.comZAK - Paid Partner Content
CymaBay Therapeutics Reports Topline 12-Week Data from an Ongoing Phase 2b Study of S...
Jun 11 / GlobeNewswirePNW - Paid Partner Content
Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash
Jun 12 / Zacks.comZAK - Paid Partner Content
Steven Cohen Takes an Interest in CymaBay Therapeutics
Jun 10 / GuruFocus NewsGURU - Paid Partner Content
Why Beyond Meat, Lovesac, and CymaBay Therapeutics Slumped Today
Jun 11 / MotleyFool.comFOO - Paid Partner Content
CymaBay Therapeutics Presents Data in Patients with Primary Biliary Cholangitis at DD...
May 20 / GlobeNewswirePNW - Paid Partner Content
Here's Why CymaBay Therapeutics Collapsed Today
Jun 11 / MotleyFool.comFOO - Paid Partner Content
 

Today’s Trading

Previous close6.75
Today’s open6.69
Day’s range6.24 - 6.80
Volume1,425,267
Average volume (3 months)1,106,983
Market cap$431.4M
Data as of 4:00pm ET, 06/14/2019

Growth & Valuation

Earnings growth (last year)-58.86%
Earnings growth (this year)-16.10%
Earnings growth (next 5 years)--
Revenue growth (last year)-100.00%
P/E ratioNM
Price/Sales--
Price/Book2.19

Competitors

 Today’s
change
Today’s
% change
DITAMCON Distributing C...+2.29+2.51%
APLSApellis Pharmaceutic...-0.22-1.03%
NUSNU Skin Enterprises ...-0.35-0.68%
HLFHerbalife Nutrition ...+0.64+1.47%
Data as of 8:00pm ET, 06/14/2019

Financials

Next reporting dateAugust 5, 2019
EPS forecast (this quarter)-$0.36
Annual revenue (last year)$0.00
Annual profit (last year)-$72.5M
Net profit margin--

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Sujal Shah
Chief Scientific Officer &
Senior Vice President
Charles A. McWherter
Corporate headquarters
Newark, California

Forecasts